{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:42:34Z","timestamp":1761100954017},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,10,19]],"date-time":"2007-10-19T00:00:00Z","timestamp":1192752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In order to assess the performance of Bayesian individualization of busulfan (BU) dosage regimens, veno\u2010occlusive disease (VOD) rate was monitored for paediatric patients undergoing allogeneic bone marrow transplantation (BMT). Consecutive patients undergoing allogeneic BMT with BU as conditioning regimen during 5\u2010years period (January 2000\u2013February 2006) were reviewed. VOD was a major outcome variable. Preconditioning risk of VOD was estimated for each patient using a scoring system that included type of transplant, recipient CMV\u2010positive status and total parenteral nutrition (TPN) provided pretransplantation. A risk\u2010adjusted cumulative sum method was used to compare observed versus predicted outcome by assigning a risk score, based on log\u2010likelihood ratios, to each patient. These cumulative scores were sequentially plotted with preset control limits for \u2018signalling\u2019 where results were substantially different than expected (doubling or halving of odds ratio). Sixty\u2010six children received BMT after oral busulfan\u2010based conditioning regimen with median age 3.9 years, 63.6% of male. Median preconditioning risk of VOD was 0.34 ranging from 0.23 to 0.84. Observed VOD rate was 16.7% (<jats:italic>n<\/jats:italic>\u2009=\u200911) which was 60.7% (17) fewer than the expected number estimated by the risk score. The resulting risk\u2010adjusted score for each patient was plotted sequentially. This plot adopted early a negative slope, crossing the lower control limit twice, after 27 and 66 patients, indicating improved results compared to those expected. Bayesian individualization of oral busulfan dosage regimens is useful to reduce the VOD rate in children undergoing allogeneic BMT. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/pds.1504","type":"journal-article","created":{"date-parts":[[2007,10,19]],"date-time":"2007-10-19T12:47:00Z","timestamp":1192798020000},"page":"135-143","source":"Crossref","is-referenced-by-count":10,"title":["Risk\u2010adjusted monitoring of veno\u2010occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics"],"prefix":"10.1002","volume":"17","author":[{"given":"Brice","family":"Kitio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Bertholle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Galambrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Mialou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Aulagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bleyzac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow LB","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.8.1723.1723"},{"key":"e_1_2_1_4_2","first-page":"31","article-title":"Graft\u2010rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery JT","year":"1995","journal-title":"Bone Marrow Transpl"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199810000-00017"},{"key":"e_1_2_1_6_2","first-page":"171","article-title":"Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis","volume":"18","author":"Styler MJ","year":"1996","journal-title":"Bone Marrow Transpl"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700985"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701334"},{"key":"e_1_2_1_9_2","first-page":"1249","article-title":"Ursodiol to prevent hepatic veno\u2010occlusive disease","volume":"31","author":"Comcowich SA","year":"1997","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_10_2","first-page":"1","article-title":"Veno\u2010occlusive disease of the liver complicating bone marrow transplantation","volume":"13","author":"Baglin TP","year":"1994","journal-title":"Bone Marrow Transpl"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703207"},{"key":"e_1_2_1_12_2","unstructured":"MontgomeryD.Introduction to statistical quality control (2nd edn). John Wiley and Sons 1991 Chapter 7 279\u2013288."},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.9r200.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/1.4.441"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/02729890122062451"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12374454"},{"key":"e_1_2_1_17_2","unstructured":"Laboratory of Applied Pharmacokinetics.1995;USC*Pack P.C. Collection Clinical Research Programs. Los Angeles. University of Southern California. School of Medicine. version 10.7."},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01070904"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020703007613"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00167-5"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704069"},{"key":"e_1_2_1_23_2","unstructured":"R [computer program]. Version 2.1.0http:\/\/cran.r\u2010projet.org;2005."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000180226.04137.75"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703229"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","article-title":"Individualizing high\u2010dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies","volume":"26","author":"Tran HT","year":"2000","journal-title":"Bone Marrow Transpl"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/088800102753356167"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780070602"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/096228020301200205"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8191.2002.01008.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2005.02.033"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01191.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200212000-00013"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701506"},{"issue":"10","key":"e_1_2_1_35_2","first-page":"1396","article-title":"A prospective survey on incidence, risk factors and therapy of hepatic veno\u2010occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro S","year":"2005","journal-title":"Haematologica"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T21:20:06Z","timestamp":1699996806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/pds.1504"],"URL":"https:\/\/doi.org\/10.1002\/pds.1504","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}